Evidence map›Paper›PMID 32847043›Full record

ArticleCancers2020

Implications of

Diana Azenha, Santiago Hernandez-Perez, Yuse Martin, Marta S Viegas, Alexandra Martins, Maria C Lopes, Eric W-F Lam, Raimundo Freire, Teresa C Martins

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Claspin and Cancer: Where Are We Now?International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Diana AzenhaFaculdade de Farmácia da Universidade de Coimbra, 3000-548 Coimbra, Portugal.
Santiago Hernandez-PerezUnidad de Investigación, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0002-2702-3857
Yuse MartinUnidad de Investigación, Hospital Universitario de Canarias, 38320 Tenerife, Spain.
Marta S ViegasNew preventive and therapeutic strategies, Centro de Neurociências e Biologia Celular, Universidade de Coimbra, 3004-504 Coimbra, Portugal.
Alexandra MartinsInserm U1245, UNIROUEN, Normandie Univ, Normandy Centre for Genomic and Personalized Medicine, 76183 Rouen, France.
Maria C LopesFaculdade de Farmácia da Universidade de Coimbra, 3000-548 Coimbra, Portugal.
Eric W-F LamDepartment of Surgery and Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine (ICTEM), London W12 0NN, UK.ORCID 0000-0003-1274-3576
Raimundo FreireUnidad de Investigación, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0003-4473-8894
Teresa C MartinsNew preventive and therapeutic strategies, Centro de Neurociências e Biologia Celular, Universidade de Coimbra, 3004-504 Coimbra, Portugal.ORCID 0000-0003-4271-2869
Instituto Português de Oncologia de Coimbra Francisco Gentil · PTHospital Universitario de Canarias · ESImperial College London · GBInserm · FRUniversidad de La Laguna · ESUniversity of Coimbra · PT

Funding

Breast Cancer Now 2012MayPR070Breast Cancer Now 2012MAYPR070Breast Cancer Now 2012NovPhD016Breast Cancer Now 2012NOVPHD016Breast Cancer Now 2014NovPhD326Cancer Research UK C37/A12011Medical Research Council MR/N012097/1
6 · The paper itself

Abstract

Claspin is a multifunctional protein that participates in physiological processes essential for cell homeostasis that are often defective in cancer, namely due to genetic changes. It is conceivable that Claspin gene (

Indexed as

breast cancercancerClaspingenetic changesglioma

Identifiers

PMID32847043
PMCPMC7565888
OpenAlexW3081139859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.